154 related articles for article (PubMed ID: 11560564)
41. Association between cardiovascular outcomes and antihypertensive drug treatment in older women.
Wassertheil-Smoller S; Psaty B; Greenland P; Oberman A; Kotchen T; Mouton C; Black H; Aragaki A; Trevisan M
JAMA; 2004 Dec; 292(23):2849-59. PubMed ID: 15598916
[TBL] [Abstract][Full Text] [Related]
42. Use of distinct anti-hypertensive drugs and risk for COVID-19 among hypertensive people: A population-based cohort study in Southern Catalonia, Spain.
Vila-Corcoles A; Satue-Gracia E; Ochoa-Gondar O; Torrente-Fraga C; Gomez-Bertomeu F; Vila-Rovira A; Hospital-Guardiola I; de Diego-Cabanes C; Bejarano-Romero F; Rovira-Veciana D; Basora-Gallisa J
J Clin Hypertens (Greenwich); 2020 Aug; 22(8):1379-1388. PubMed ID: 32710674
[TBL] [Abstract][Full Text] [Related]
43. A cohort study of antihypertensive medication use and breast cancer among Danish women.
Fryzek JP; Poulsen AH; Lipworth L; Pedersen L; Nørgaard M; McLaughlin JK; Friis S
Breast Cancer Res Treat; 2006 Jun; 97(3):231-6. PubMed ID: 16791484
[TBL] [Abstract][Full Text] [Related]
44. Preadmission use of renin-angiotensin blockers and rupture of abdominal aortic aneurysm: a nationwide, population-based study.
Wemmelund H; Høgh A; Hundborg HH; Johnsen SP; Lindholt JS
Pharmacoepidemiol Drug Saf; 2016 Feb; 25(2):141-50. PubMed ID: 26817783
[TBL] [Abstract][Full Text] [Related]
45. Angiotensin-Converting Enzyme Inhibitors or Angiotensin Receptor Blockers Use and COVID-19 Infection Among 824 650 Patients With Hypertension From a US Integrated Healthcare System.
An J; Wei R; Zhou H; Luong TQ; Gould MK; Mefford MT; Harrison TN; Creekmur B; Lee MS; Sim JJ; Brettler JW; Martin JP; Ong-Su AL; Reynolds K
J Am Heart Assoc; 2021 Feb; 10(3):e019669. PubMed ID: 33307964
[TBL] [Abstract][Full Text] [Related]
46. Comparison Between Beta-Blockers with Angiotensin-Converting Enzyme Inhibitors and Beta-Blockers with Angiotensin II Type I Receptor Blockers in ST-Segment Elevation Myocardial Infarction After Successful Percutaneous Coronary Intervention with Drug-Eluting Stents.
Kim YH; Her AY; Jeong MH; Kim BK; Lee SY; Hong SJ; Shin DH; Kim JS; Ko YG; Choi D; Hong MK; Jang Y
Cardiovasc Drugs Ther; 2019 Feb; 33(1):55-67. PubMed ID: 30632033
[TBL] [Abstract][Full Text] [Related]
47. [Consumption of antihypertensive agents in obese patients: a cross-sectional study in a sample of 3,291 wage-earners in the Toulous region].
Lapeyre-Mestre M; Sulem P; Chastan E; Niezborala M; Briant D; Jansou P; Sanguignol F; Montastruc JL
Arch Mal Coeur Vaiss; 2000 Aug; 93(8):925-9. PubMed ID: 10989731
[TBL] [Abstract][Full Text] [Related]
48. Beta-blockers, calcium channel blockers, angiotensin converting enzyme inhibitors and angiotensin receptor blockers: should they be stopped or not before ambulatory anaesthesia?
Smith I; Jackson I
Curr Opin Anaesthesiol; 2010 Dec; 23(6):687-90. PubMed ID: 20805745
[TBL] [Abstract][Full Text] [Related]
49. Preadmission Antihypertensive Drug Use and Sepsis Outcome: Impact of Angiotensin-Converting Enzyme Inhibitors (ACEIs) and Angiotensin Receptor Blockers (ARBs).
Hsieh MS; How CK; Hsieh VC; Chen PC
Shock; 2020 Apr; 53(4):407-415. PubMed ID: 31135703
[TBL] [Abstract][Full Text] [Related]
50. Antihypertensive Use and the Risk of Cataract in Patients with Hypertension: A Nationwide Case-control Study.
Yang HL; Byun SJ; Park S; Lee SH; Park SJ; Jung SY
Ophthalmic Epidemiol; 2023 Oct; 30(5):499-508. PubMed ID: 36369827
[TBL] [Abstract][Full Text] [Related]
51. First-line drugs inhibiting the renin angiotensin system versus other first-line antihypertensive drug classes for hypertension.
Chen YJ; Li LJ; Tang WL; Song JY; Qiu R; Li Q; Xue H; Wright JM
Cochrane Database Syst Rev; 2018 Nov; 11(11):CD008170. PubMed ID: 30480768
[TBL] [Abstract][Full Text] [Related]
52. Long-term use of antihypertensive drugs and risk of cancer.
Assimes TL; Elstein E; Langleben A; Suissa S
Pharmacoepidemiol Drug Saf; 2008 Nov; 17(11):1039-49. PubMed ID: 18780400
[TBL] [Abstract][Full Text] [Related]
53. Initial Antihypertensive Regimens in Newly Treated Patients: Real World Evidence From the OneFlorida+ Clinical Research Network.
Smith SM; Winterstein AG; Gurka MJ; Walsh MG; Keshwani S; Libby AM; Hogan WR; Pepine CJ; Cooper-DeHoff RM
J Am Heart Assoc; 2023 Jan; 12(1):e026652. PubMed ID: 36565195
[TBL] [Abstract][Full Text] [Related]
54. β-Blockers and All-Cause Mortality in Adults with Episodes of Acute Bronchitis: An Observational Study.
Rutten FH; Groenwold RH; Sachs AP; Grobbee DE; Hoes AW
PLoS One; 2013; 8(6):e67122. PubMed ID: 23840599
[TBL] [Abstract][Full Text] [Related]
55. Reexamining the Effect of Antihypertensive Medications on Falls in Old Age.
Lipsitz LA; Habtemariam D; Gagnon M; Iloputaife I; Sorond F; Tchalla AE; Dantoine TF; Travison TG
Hypertension; 2015 Jul; 66(1):183-9. PubMed ID: 25941341
[TBL] [Abstract][Full Text] [Related]
56. Calcium channel blockers: third-line antihypertensives.
Prescrire Int; 2001 Aug; 10(54):121-3. PubMed ID: 11718186
[TBL] [Abstract][Full Text] [Related]
57. A survey of outpatient management of elderly heart failure patients in Poland-treatment patterns.
Rywik TM; Rywik SL; Korewicki J; Broda G; Sarnecka A; Drewla J
Int J Cardiol; 2004 Jun; 95(2-3):177-84. PubMed ID: 15193817
[TBL] [Abstract][Full Text] [Related]
58. Angiotensin-converting enzyme inhibitors/angiotensin receptor blockers, β-blockers or both in incident end-stage renal disease patients without cardiovascular disease: a propensity-matched longitudinal cohort study.
Ferreira JP; Couchoud C; Gregson J; Tiple A; Glowacki F; London G; Agarwal R; Rossignol P
Nephrol Dial Transplant; 2019 Jul; 34(7):1216-1222. PubMed ID: 30590716
[TBL] [Abstract][Full Text] [Related]
59. First-line drugs for hypertension.
Wright JM; Musini VM; Gill R
Cochrane Database Syst Rev; 2018 Apr; 4(4):CD001841. PubMed ID: 29667175
[TBL] [Abstract][Full Text] [Related]
60. Potential oral manifestations of cardiovascular drugs.
Habbab KM; Moles DR; Porter SR
Oral Dis; 2010 Nov; 16(8):769-73. PubMed ID: 20604876
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
